Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a Late-Stage clot buster help stroke patients without surgery?

NCT ID NCT07168278

Not yet recruiting Disease control Sponsor: The First Affiliated Hospital of University of Science and Technology of China Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether the clot-busting drug tenecteplase can improve recovery in people who have a major stroke caused by a large blocked artery, but who cannot have a procedure to remove the clot. The trial includes 794 adults who arrive at the hospital 4.5 to 24 hours after their stroke started. Participants receive either tenecteplase or standard medical care, and the main goal is to see if more people are independent at 90 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Tenecteplase (a clot-busting drug)
What this could lead to
If it works, this could provide a treatment option for stroke patients who miss the early window or cannot get mechanical clot removal.
What could go wrong
This is a large phase 3 trial, but tenecteplase carries a risk of bleeding, and the benefit in this later time window (4.5-24 hours) is unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cerebral artery occlusion ischemic stroke large artery stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE ISCHEMIC STROKE LARGE VESSEL OCCLUSION TENECTEPLASE THROMBOLYSIS

Contacts and locations

Locations

  • The First Affiliated Hospital of University of Science and Technology of China

    Hefei, Anhui, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.